Responses
Clinical/translational cancer immunotherapy
Original research
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
Compose a Response to This Article
Other responses
No responses have been published for this article.